{"groups":[{"description":"80 mg of paclitaxel per square meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, for a total of 12 doses. After the completion of 12 weeks of treatment with Trastuzumab, the dosing of Trastuzumab 6mg/kg over 3 weeks to complete a full year of intravenous treatment with trastuzumab.","id":"FG000","title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"31"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"30"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Recurrent disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"unknown reason"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"10"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"406"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"327"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"79"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}